NASDAQ · RGLS
Healthcare · Biotechnology
$8.16
Up+$0.00 (+0.00%)
Updated Aug 16, 2026, 6:58 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RGLS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning RGLS.
RGLS research
Company profile and research snapshot.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 1, 2025 | Wells Fargo | Equal-Weight | — |
| Apr 30, 2025 | Canaccord Genuity | Hold | — |
| Apr 30, 2025 | Leerink Partners | Market Perform | — |
| Apr 30, 2025 | Jones Trading | Hold | — |
| Mar 27, 2025 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jun 1, 2025
Novartis announces data from a subgroup analysis of the NATALEE trial, showing that Kisqali plus endocrine therapy reduced the risk of recurrence in pre-menopausal and younger patients with early breast cancer.
Benzinga · Apr 30, 2025
Novartis has agreed to acquire Regulus Therapeutics, a clinical-stage biopharmaceutical company developing microRNA therapeutics for kidney diseases, for an initial payment of $800 million. The deal could reach $1.7 billion if Regulus' lead product candidate, farabursen, gains regulatory approval.
Benzinga · Jun 25, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan cut the price target for Sea Limited (NYSE:SE) from $84 to $78. JP Morgan analyst Ranjan Sharma downgraded the stock from Overweight to Neutral. Sea shares gained 0.6% to close at $75.89 on Monday. See how other analysts view this stock. Morgan Stanley raised the price target for Birkenstock Holding plc (NYSE:BIRK) from $44 to $58. Morgan Stanley analyst Edouard Aubin maintained an Equal-Weight rating. Birkenstock shares fell 2.8% to close at $59.78 on Monday. See how other analysts view this stock. TD Cowen boosted Credo Technology Group Holding Ltd (NASDAQ:CRDO) price target from $24 to $35. TD Cowen analyst Matt Ramsay upgraded the stock from Hold to Buy. Credo ...Full story available on Benzinga.com
Zacks Investment Research · Mar 14, 2024
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RGLS.
No results
No recent SID articles mention RGLS.
